Suggested remit: To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating untreated advanced RET fusion-positive thyroid cancer and untreated advanced RET mutation-positive medullary thyroid cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6132
|
Project Team
| Project lead |
Celia Mayers |
Email enquiries
| External Assessment Group |
Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors |
Eli Lilly (selpercatinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
AMEND (Association for Multiple Endocrine Neoplasia Disorders) |
| |
British Thyroid Foundation |
| |
Butterfly Thyroid Cancer Trust |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bayer (sorafenib) – confidentiality agreement not signed, not participating |
| |
Eisai (lenvatinib) |
| |
Ipsen (cabozantinib) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
05 September 2024 - 19 September 2024
|
Final draft guidance |
|
12 June 2024
|
Committee meeting: 2 |
|
12 June 2024
|
Declaration of interests |
|
01 May 2024 - 23 May 2024
|
Draft guidance |
|
10 April 2024
|
Committee meeting |
|
23 August 2023
|
Invitation to participate |
|
11 July 2023 - 08 August 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
11 July 2023
|
In progress. Scoping commenced |
|
16 May 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual